Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of cladribine powder in China. Welcome to wholesale bulk high quality cladribine powder for sale here from our factory. Good service and reasonable price are available.
Cladribine Powder is a chemical substance that appears as a white or off white crystalline powder, slightly soluble in water, soluble in dimethyl sulfoxide, slightly soluble in methanol, and almost insoluble in acetonitrile. Cladribine is a chlorinated purine nucleotide analogue that can inhibit DNA synthesis and repair.
It acts on adenosine deaminase, blocks the repair of damaged DNA, inhibits DNA methylation, and has anti lymphoma activity. It can induce the accumulation of DNA strand breaks and subsequently activate the tumor suppressor gene p53 in lymphocytes, thereby exerting cytotoxic effects. It may also exert immunomodulatory effects by regulating certain signaling pathways in the immune system, such as reducing NLRP3 inflammasome activation and regulating amyloid beta autophagy. It has significant therapeutic effects on hairy cell leukemia and can prolong the complete remission period. Meanwhile, it also has certain therapeutic effects on other lymphomas and leukemia.
 |
 |
Additional information of chemical compound:
|
Product Name |
Cladribine Powder |
|
Product Type |
Powder |
|
Product Purity |
100g/1kg/etc. |
|
Product Form |
Organic synthesis |
|
|
|
Cdp Choline Bulk
 |
||
|
|
||
|
|
Cladribine Powder, as an important chemical substance, has a wide range of application value in the medical field. The following will elaborate on its purpose from multiple aspects:
Treat blood system diseases
Cladribine is the first-line standard treatment for hairy cell leukemia (HCL). Hair cell leukemia is a rare chronic lymphocytic proliferative disease characterized by the presence of hair cells in peripheral blood and bone marrow. These hair cells have unique morphological and immunophenotypic characteristics and do not respond well to conventional chemotherapy drugs. Clavubine achieves therapeutic goals by inhibiting DNA synthesis and repair, inducing apoptosis of hair cells. The commonly used dose of clarithromycin in the treatment of hairy cell leukemia is 0.09mg/kg/d, administered continuously for 24 hours for 7 days. Multiple clinical studies have shown that the complete response rate (CR) of clarithromycin in the treatment of hairy cell leukemia can reach over 90%, and the partial response rate (PR) can also reach a certain proportion. In addition, the efficacy of clarithromycin in treating hairy cell leukemia is long-lasting, and many patients can maintain a long-term remission state after receiving treatment. During the treatment process, it is necessary to closely monitor the patient's blood routine indicators and promptly detect and treat adverse reactions such as bone marrow suppression. At the same time, active anti infective treatment should be given to patients who have been infected.
Mantle cell lymphoma
Cladribine Powder can be used for first-line and second-line treatment of mantle cell lymphoma (MCL). Mantle cell lymphoma is a type of non Hodgkin lymphoma characterized by invasiveness and refractory nature. Cladribine exerts anti-tumor effects by inhibiting the proliferation of tumor cells and inducing cell apoptosis. When treating mantle cell lymphoma, clarithromycin is often used in combination with other chemotherapy drugs to improve treatment efficacy. For example, the RC regimen (combining clarithromycin and rituximab) can be used for the treatment of relapsed and refractory B-cell lymphoma. The dose of clarithromycin is 5mg/(m ² · d), administered intravenously for 2 hours for 5 consecutive days. Rituximab is a monoclonal antibody targeting CD20 antigen that can specifically kill B-cell lymphoma cells. The combination of clarithromycin and rituximab can exert synergistic anti-tumor effects and improve treatment efficacy. Multiple clinical studies have shown that the combination of clarithromycin and rituximab is effective in treating mantle cell lymphoma, with improved complete and partial response rates in patients. At the same time, the safety of this scheme is also good, and adverse reactions are controllable. However, due to the heterogeneity and refractory nature of mantle cell lymphoma, some patients may be insensitive to treatment options such as clarithromycin or experience recurrence.
Cladribine is one of the important drugs in salvage chemotherapy regimens for refractory/relapsed acute myeloid leukemia (AML). AML is a malignant clonal disease originating from bone marrow hematopoietic stem cells, characterized by high heterogeneity and refractory nature. Cladribine exerts anti-tumor effects by inhibiting the proliferation of leukemia cells and inducing cell apoptosis. When treating refractory/recurrent AML, cladribine is often used in combination with other chemotherapy drugs to improve treatment efficacy. For example, the CLAG regimen (clarithromycin, cytarabine, and granulocyte colony-stimulating factor) can be used for the treatment of relapsed and refractory AML. The dose of clarithromycin is 5mg/(m ² · d), administered intravenously for 2 hours for 5 consecutive days; Cytarabine 1-2g/(m ² · d), intravenous infusion for 4 hours, to be used 2 hours after clarithromycin, for 5 consecutive days; Granulocyte colony-stimulating factor 5 μ g/(Kg · d), subcutaneous injection (S.C.) or intravenous drip, qd, 24 hours before the infusion of clarithromycin, when WBC>20 × 10 ⁹/L, G-CSF and clarithromycin should be used simultaneously for 6 consecutive days. The CLAG regimen enhances the anti leukemia effect through drug synergy, especially suitable for patients who have poor response to traditional chemotherapy.
Fahrenheit macroglobulinemia&other rare hematological malignancies
Cladribine can also be used for the treatment of Fahrenheit macroglobulinemia (WM). WM is a low-grade malignant lymphoma originating from lymphoplasmacytes, characterized by elevated levels of monoclonal immunoglobulin M (IgM) in the serum. Cladribine exerts anti-tumor effects by inhibiting the proliferation of WM cells and inducing cell apoptosis. However, compared with hairy cell leukemia and mantle cell lymphoma, the use of clarithromycin in WM treatment is relatively limited, and its efficacy and safety still need further evaluation. In addition, clarithromycin can also be used for the treatment of other rare hematological malignancies, such as lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, etc. However, due to the low incidence rate of these diseases, the specific application scheme and efficacy of cladribine in these diseases need further research and verification.
Application in scientific research
The highly selective toxicity of clarithromycin to lymphocytes makes it an important tool for studying lymphocyte function. When studying the proliferation, differentiation, and function of T cells and B cells, clarithromycin can be used for in vitro cultivation of lymphocytes to observe its inhibitory effect on lymphocyte proliferation and its impact on cell differentiation. By comparing the phenotypic changes and cytokine secretion of lymphocytes treated with different concentrations of clarithromycin, we can gain a deeper understanding of the functional characteristics of lymphocytes under different physiological and pathological states. When studying the apoptosis mechanism of lymphocytes, clavulanic acid can be used as an agent to induce apoptosis. Studying the signaling pathway and expression changes of apoptosis related proteins induced by clavulanic acid can help reveal the molecular mechanism of lymphocyte apoptosis and provide a theoretical basis for the treatment of lymphocyte related diseases.
Application in Immunological Research
Cladribine also has certain applications in the study of autoimmune diseases. When studying the pathogenesis of autoimmune diseases such as multiple sclerosis (MS), clarithromycin can be used to regulate immune system function. Due to multiple sclerosis being an autoimmune disease, the patient's immune system mistakenly attacks the myelin sheath of the central nervous system. Cladribine can simulate the therapeutic effect of treating multiple sclerosis in animal models by inhibiting the proliferation of T and B cells, reducing the immune system's attack on the nervous system. By studying the changes in disease condition, immune cell composition, and function in animal models treated with clarithromycin, we can gain a deeper understanding of the pathogenesis of autoimmune diseases such as multiple sclerosis, and provide a basis for developing new therapeutic drugs and methods. In addition, clarithromycin can also be used to study other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, etc., exploring its potential in regulating immune system function and treating autoimmune diseases.
Clavudine can interfere with DNA synthesis and induce cell apoptosis, therefore it has important applications in cell cycle and apoptosis research. When studying the mechanism of cell cycle regulation, clarithromycin can be used to treat cells and observe its effect on cell cycle progression. By analyzing the changes in cell cycle distribution through techniques such as flow cytometry, it is possible to determine at which stage of the cell cycle Clavudine blocks cells, and further study the expression and activity changes of related cell cycle regulatory proteins, thereby revealing the molecular mechanism of Clavudine affecting the cell cycle. When studying the apoptotic signaling pathway, clarithromycin can be used as an agent to induce apoptosis. By detecting the expression and activity changes of apoptosis related proteins such as caspase family proteins and Bcl-2 family proteins, as well as observing changes in cell morphology, we can further investigate the signal transduction pathway of clavulanic acid-induced cell apoptosis, providing important information for understanding the regulatory mechanism of cell apoptosis.
Application in Cell Biology Research
Cladribine Powder can inhibit DNA synthesis and repair, and therefore has applications in DNA damage and repair research. When studying the mechanism of DNA damage response, clarithromycin can be used to treat cells and induce DNA damage. By detecting DNA damage markers such as the formation of gamma H2AX foci and the repair of DNA double strand breaks, the response of cells to clavulanic acid-induced DNA damage, as well as the functions and regulatory mechanisms of related DNA damage repair proteins, can be studied. In addition, clarithromycin can also be used to study the relationship between DNA damage and biological processes such as cell apoptosis and cell cycle arrest. By using other DNA damaging agents or repair inhibitors in combination, we can further understand the role of DNA damage in cell fate determination, providing a theoretical basis for fields such as tumor therapy and radiation protection.
Hot Tags: cladribine powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, articaine hydrochloride powder, pure benzocaine powder, ciprofloxacin powder, D Pantothenic Acid Hemicalcium Salt CAS 137 08 6, 1 3 Dimethylpentylamine, 1 5 Dimethylhexylamine